In Canada v. Glaxosmithkline Biologicals
S.A.1, the Federal Court of Appeal (FCA) upheld the
Minister of Health's refusal to issue a Certificate of
Supplementary Protection (CSP) to GSK for its SHINGRIX vaccine.
Overturning the application judge, the FCA concluded that the
Minister's determination that the relevant patent did not
contain "a claim for the medicinal ingredient" in
SHINGRIX, as required by the CSP Regulations, was
reasonable.
The decision marks the first opportunity that the FCA has had to
consider the patent eligibility criteria under Canada's CSP
Regulations, and in particular, the interpretation of the
phrase "a claim for the medicinal ingredient".
What you need to know